Log ind

Novo’s US head is ready for turnaround

38642339.jpg Top picks in English:

The head of Novo Nordisk’s North American business, Jakob Riis, has made the necessary changes to facilitate a turnaround in his first five months in the job. He now has the freedom and room to maneuver that should lead to twice as big a share of the market for the group's major insulin hope.

Genmab has reinforced foundation with ASH data

Genmab’s bone marrow cancer treatment has delivered the goods with fresh data presented at a hematology conference in San Diego. It reinforces the drug’s position in the market and the entire future foundation for the Danish biotech company, says an analyst.

Novo’s science chief says he is not letting go of the Holy Grail

Although Novo Nordisk has discontinued its activities in what CSO Mads Krogsgaard Thomsen has previously called the Holy Grail of diabetes care, he is not resigned to letting go completely. A partnership with the world’s most cited researcher could bring Novo back in the game. But for now, he has turned his attention to another Holy Grail.

ANNONCE


ANNONCE